HK1017681A1 - Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox - Google Patents

Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox

Info

Publication number
HK1017681A1
HK1017681A1 HK99102767A HK99102767A HK1017681A1 HK 1017681 A1 HK1017681 A1 HK 1017681A1 HK 99102767 A HK99102767 A HK 99102767A HK 99102767 A HK99102767 A HK 99102767A HK 1017681 A1 HK1017681 A1 HK 1017681A1
Authority
HK
Hong Kong
Prior art keywords
crystal modification
trifluoromethylphenyl
lines
crystal
intensity
Prior art date
Application number
HK99102767A
Other languages
English (en)
Inventor
Holger Faasch
Udo Hedtmann
Uwe Westenfelder
Erich Paulus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of HK1017681A1 publication Critical patent/HK1017681A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK99102767A 1997-08-08 1999-06-30 Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox HK1017681A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
HK1017681A1 true HK1017681A1 (en) 1999-11-26

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
HK99102767A HK1017681A1 (en) 1997-08-08 1999-06-30 Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox
HK03101247.6A HK1049481B (zh) 1997-08-08 2003-02-19 結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK03101247.6A HK1049481B (zh) 1997-08-08 2003-02-19 結晶形式的n-(4-三氟甲基苯基)-5-甲基異噁唑-4-甲酰胺的製備方法

Country Status (28)

Country Link
US (5) US6060494A (no)
EP (2) EP0903345B1 (no)
JP (2) JPH11124372A (no)
KR (2) KR100544041B1 (no)
CN (2) CN1089759C (no)
AR (1) AR015418A1 (no)
AT (2) ATE207065T1 (no)
AU (1) AU752764B2 (no)
BR (1) BR9806568A (no)
CA (1) CA2245267C (no)
CZ (3) CZ301426B6 (no)
DE (2) DE59800287D1 (no)
DK (2) DK0987256T3 (no)
ES (2) ES2166205T3 (no)
GR (1) GR3034814T3 (no)
HK (2) HK1017681A1 (no)
HU (2) HU229232B1 (no)
ID (1) ID20667A (no)
IL (1) IL125671A (no)
NO (1) NO310871B1 (no)
NZ (1) NZ331270A (no)
PL (1) PL192126B1 (no)
PT (2) PT987256E (no)
RU (1) RU2224753C2 (no)
SK (2) SK282641B6 (no)
TR (2) TR200600582A1 (no)
TW (1) TW593288B (no)
UA (1) UA54411C2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CZ20022000A3 (cs) 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
WO2003068239A1 (fr) * 2002-02-12 2003-08-21 Sumitomo Pharmaceuticals Co., Ltd. Nouveaux medicaments d'usage externe
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
CA2671369C (en) * 2008-03-10 2011-05-10 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
US20120172427A1 (en) 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
DE59407413D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
TW314467B (no) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1996011682A1 (fr) * 1994-10-17 1996-04-25 Hoechst Pharmaceuticals & Chemicals K.K. Composition preventive et remede pour les maladies allergiques de type i
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
US6221891B1 (en) 2001-04-24
SK282641B6 (sk) 2002-10-08
TR200600582A1 (tr) 2006-08-21
PT987256E (pt) 2002-03-28
KR20050077498A (ko) 2005-08-02
US20030166945A1 (en) 2003-09-04
JPH11124372A (ja) 1999-05-11
RU2224753C2 (ru) 2004-02-27
JP2009280604A (ja) 2009-12-03
ID20667A (id) 1999-02-11
DK0903345T3 (da) 2000-10-23
CN1089759C (zh) 2002-08-28
US20030027851A1 (en) 2003-02-06
ES2166205T3 (es) 2002-04-01
AU7887098A (en) 1999-02-18
DK0987256T3 (da) 2002-02-11
SK285216B6 (sk) 2006-09-07
EP0987256B1 (de) 2001-10-17
IL125671A0 (en) 1999-04-11
IL125671A (en) 2002-11-10
ATE196764T1 (de) 2000-10-15
BR9806568A (pt) 2000-05-16
CN1208034A (zh) 1999-02-17
CZ292943B6 (cs) 2004-01-14
EP0987256A1 (de) 2000-03-22
CZ246898A3 (cs) 1999-02-17
HK1049481A1 (en) 2003-05-16
KR100588254B1 (ko) 2006-06-12
KR100544041B1 (ko) 2006-09-18
PL192126B1 (pl) 2006-09-29
EP0903345B1 (de) 2000-10-04
CZ301426B6 (cs) 2010-02-24
HU0700190D0 (en) 2007-05-02
HU9801844D0 (en) 1998-10-28
AR015418A1 (es) 2001-05-02
TR199801513A2 (xx) 1999-02-22
ES2150808T3 (es) 2000-12-01
CZ301514B6 (cs) 2010-03-31
SK105898A3 (en) 1999-02-11
CA2245267C (en) 2008-12-23
CA2245267A1 (en) 1999-02-08
NO983632D0 (no) 1998-08-07
HK1049481B (zh) 2005-07-08
TW593288B (en) 2004-06-21
US6995272B2 (en) 2006-02-07
NO310871B1 (no) 2001-09-10
DE59800287D1 (de) 2000-11-09
PT903345E (pt) 2001-01-31
TR199801513A3 (tr) 1999-02-22
HU229232B1 (en) 2013-09-30
US6552202B2 (en) 2003-04-22
HUP9801844A3 (en) 2000-04-28
KR19990023433A (ko) 1999-03-25
ATE207065T1 (de) 2001-11-15
DE59801792D1 (de) 2001-11-22
HUP9801844A2 (hu) 2000-02-28
UA54411C2 (uk) 2003-03-17
NO983632L (no) 1999-02-09
HU225870B1 (en) 2007-11-28
EP0903345A1 (de) 1999-03-24
CN1373126A (zh) 2002-10-09
AU752764B2 (en) 2002-09-26
US6060494A (en) 2000-05-09
GR3034814T3 (en) 2001-02-28
CN1181064C (zh) 2004-12-22
PL327901A1 (en) 1999-02-15
US6900334B2 (en) 2005-05-31
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
HK1017681A1 (en) Crystal from of n-(4-trifluoromethylphenyl)-5-methylisox
AU7010694A (en) A surgical instrument, particularly for operative treatment of the prostate gland
AU6350699A (en) Chemical compounds
WO2000003749A3 (en) Method for regulating hair growth
AU6613896A (en) Chemical compounds
NO993247L (no) Fremgangsmåte for fremstilling av tolterodin
AU2427297A (en) Apparatus for facilitating the placement of sutures, ligatures and the like
AU1926197A (en) Preparation containing a combination of 5-methylisoxazole-4 -carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
AU2343995A (en) Novel benzofused 5-membered heterocyclic rings for the treatment of migraine
AU3224497A (en) Processes for the synthesis of sialyl lewisx compounds
NO984344L (no) Ny asymmetriske syntese av R-<alfa>-propylpiperonyalamin og dets analoger
NO986086D0 (no) FremgangsmÕte for fremstilling av 17-estere av 9<alfa>,21-dihalo-pregnan-11
WO1998017230A3 (en) New 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives
MX9100560A (es) Integron de corinebacterias,procedimiento para la transformacion corinebacteria mediante dicho integron y corinebacteria obtenida
AU7610781A (en) 4h-3,1-benzoxazine
GR3005254T3 (no)
NZ330464A (en) Methods for the preparation of biphenyl isoxazole sulfonamides
NO20000182L (no) Fremgangsmåte for fremstilling av alkoksyfuranonamin- derivater, forbindelser frembragt ved fremgangsmåten og anvendelse av disse forbindelser
EP1116720A4 (en) PROCESS FOR THE PREPARATION OF ISOCHROMANONES AND INTERMEDIATES USED FOR THEIR PREPARATION
ZA974679B (en) New use of derivatives of cystine.
AU2076195A (en) Novel 3-(omega-(4-benzoylpiperidino)alkyl)-4h-benzopyran-4-ones, preparation and therapeutical use thereof
ES2156605T3 (es) Procedimiento de preparacion de un 3,5-hidrato de dihidrocloruro de 3-(2-(4-(3-cloro-2-metilfenil)-1-piperazinil)etil)-5,6-dimetoxi-1-(4-imidazolilmetil)-1h-indazol.
Shtyrlin et al. Effect of treatment and synthesis temperature on phase ratio and microhardness of submicron carbon films; Vliyanie ionnoj obrabotki i temperatury sinteza na sootnoshenie faz i mikrotverdost'submikronnykh uglerodnykh plenok
AU1128295A (en) Compounds and methods for synthesizing pantethine, pantetheine and derivatives thereof
ZA9510829B (en) 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20180806